SpectronRx

We're excited to share a significant milestone in SpectronRx's journey—our Expansion into Europe! Just in time for #EANM24, we've inked a binding agreement to establish our first European radiolabeling facility at the Belgian Nuclear Research Center (SCK CEN) in Mol, Belgium. This state-of-the-art rCDMO facility is set to revolutionize our capabilities in radiopharmaceutical production, with a special focus on actinium-225-based radiopharmaceuticals. Construction is expected to conclude by November 2024, and operations are scheduled to kick off in Q1 2025, pending GMP certification approval. You can read more about our expansion plans in today's FiercePharma. https://lnkd.in/gaYriU6t #Radiopharmaceuticals #PharmaInnovation #EuropeanExpansion #CancerTreatment #NuclearMedicine #CDMO

Are you attending the European Association of Nuclear Medicine's annual congress in Hamburg from October 19-23? Be sure to visit us at booth S29 and discover how SpectronRx can revolutionize your radiopharmaceutical development and manufacturing processes. We look forward to seeing you there! https://eanm24.eanm.org/ #Radiopharmaceuticals #NuclearMedicine #EANM24

Arterial vs. Venous Delivery of PSMA PET/CT Radioligand Infusions in Primary Prostatic Adenocarcinoma - What Does the Research Say? A recent study, conducted by experts from UCSF's Department of Radiology and Biomedical Imaging, alongside the Departments of Pathology and Urology, has brought new insights into the delivery methods for PSMA PET/CT radioligand infusions in primary prostatic adenocarcinoma. The study evaluates the effectiveness of intravenous versus prostatic arterial infusions, with a focus on whether infusions through the right or left prostatic artery would yield different results compared to the traditional intravenous method. The findings? Selective prostatic arterial infusion resulted in significantly greater tumoral uptake compared to the intravenous approach. For a detailed exploration of this research, read the full study here:?https://lnkd.in/gySJGzWu #NuclearMedicine?#Radiopharmaceuticals

A giant thank you to UroToday + GU OncToday for sharing the news about our newest partnership with Clarity Pharmaceuticals. You can read all about it HERE: https://lnkd.in/gP3btTgP #NuclearMedicine #Radiopharmaceuticals #CDMO

Are you headed to historic Hamburg, Germany, for the European Association of Nuclear Medicine (EANM) annual congress? If so, be sure to visit us at booth S29. SpectronRx's very own Anwer Rizvi, Peter Webner, Tim Vertz and Rudi Verbruggen will be on hand to discuss how SpectronRx can support your European radiopharmaceutical development and manufacturing needs. We can't wait to see you there! https://eanm24.eanm.org/ #Radiopharmaceuticals #NuclearMedicine #EANM24

???We have some exciting news to share! Clarity Pharmaceuticals has signed a Clinical Manufacturing Agreement with us, enhancing our joint commitment to innovative healthcare solutions. This new agreement builds upon our previous Master Services and Supply Agreements, focusing on the streamlined production of the 64Cu isotope and the 64Cu-SAR-bisPSMA product at a single facility. As part of the agreement, SpectronRx will ensure reliable, on-demand manufacturing and distribution of Clarity’s novel diagnostic, 64Cu-SAR-bisPSMA, across all 50 states. This will enable universal access to Clarity’s Phase III trials, including the ongoing CLARIFY trial and the upcoming pivotal trial for prostate cancer patients experiencing biochemical recurrence (BCR). This partnership enhances Clarity’s supply network with a robust, multifaceted approach unique to the radiopharmaceutical sector. Why is this significant? It guarantees a continuous and ample supply chain, providing widespread access to 64Cu-SAR-bisPSMA throughout the United States. ???You can read the full announcement in today's edition of?BioSpace:?https://lnkd.in/gzJWN5FT #NuclearMedicine #Radiopharmaceuticals #ClinicalTrials #SpectronRx #ClarityPharmaceuticals

???Happy Nuclear Medicine and Molecular Imaging Week! This week, we celebrate the incredible people and innovations transforming how we diagnose, treat and care for patients. From cutting-edge imaging techniques to novel treatments, nuclear medicine is shaping the future of healthcare, one dose at a time. ??Join us in acknowledging the incredible work and innovation driving our field forward! https://lnkd.in/gCXJUZJq #NMW #MolecularImaging #SNMMI #NuclearMedicine #Radiopharmaceuticals

?? Exciting news from GE HealthCare! Congratulations to the team on receiving FDA approval for Flurpiridaz F-18 (Flyrcado), a groundbreaking PET imaging agent designed for adult patients with known or suspected coronary artery disease (CAD). ?? CAD is the leading cause of death in the U.S., often resulting from narrowed or blocked coronary arteries that can lead to serious conditions like myocardial ischemia and heart attacks. Flurpiridaz F-18 is a nuclear medicine tracer used in myocardial perfusion imaging (MPI) tests, which assess blood flow to the heart muscle under both rest and stress conditions. With its longer half-life of 109 minutes, Flurpiridaz F-18 offers improved diagnostic accuracy compared to the current standard of SPECT MPI, allowing for broader distribution and enhanced image quality. This advancement marks a significant leap forward in cardiac imaging, particularly for hard-to-image patients, such as those with high body mass index and women, for whom traditional imaging can be less accurate. ?? Want to learn more about Flurpiridaz F-18 and its potential impact on cardiac care? Check out the full article here: https://lnkd.in/ghcPvEfN #HealthcareInnovation #NuclearMedicine #Cardiology #Radiopharmaceuticals

Exciting developments in the world of oncology! A Phase II clinical study has revealed that Lu-177-Dotatate, a radiopharmaceutical initially used for neuroendocrine tumors, shows promise in extending progression-free survival for patients battling meningioma, the most common type of primary brain tumor. In the groundbreaking study, nearly 80% of participants remained progression-free after six months. This significant result surpasses historical benchmarks, indicating that radiopharmaceuticals like 177Lu-Dotatate could offer a more effective treatment option compared to traditional methods such as surgery or radiation. You can read more about the study here: https://lnkd.in/gigcNB-A #NuclearMedicine #Oncology #Radiopharmaceuticals #MeningiomaTreatment

Join Us at EANM 2024 in Hamburg! We're thrilled to announce that SpectronRx will be participating in the European Association of Nuclear Medicine (EANM) annual congress, taking place in historic Hamburg, Germany, from October 19-23. Planning to attend? Don’t miss the chance to visit us at booth S29. Our team—Anwer Rizvi, Peter Webner, Tim Vertz and Rudi Verbruggen—will be on hand to discuss how SpectronRx can support your radiopharmaceutical development and manufacturing needs. We can't wait to see you there! https://eanm24.eanm.org/ #Radiopharmaceuticals #NuclearMedicine #EANM24